Form 4: Allakos Inc. Director James Steven P. Reports Cancellation of Stock Options Following Merger Agreement

Director James Steven P. reports the cancellation of several stock options in Allakos Inc. following the merger agreement with Concentra Biosciences, LLC and Concentra Merger Sub III, Inc.

Summary

• James Steven P., a director of Allakos Inc., filed a Form 4 on May 15, 2025, reporting changes in beneficial ownership.
• The report indicates the cancellation of several stock options held by James Steven P.
• These cancellations are related to the Agreement and Plan of Merger dated April 1, 2025, between Allakos Inc., Concentra Biosciences, LLC, and Concentra Merger Sub III, Inc.
• The cancelled options had various exercise prices and expiration dates, ranging from $0.525 to $99.83.
• The total number of cancelled options amounts to 332,932 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports a procedural consequence of a merger agreement. The cancellation of stock options is neither inherently positive nor negative without further context.

Negatives

• The cancellation of stock options could be perceived negatively by some, as it reduces the potential future equity stake of the director.

Risks

• The merger itself could present integration risks or other unforeseen challenges.
• The cancellation of stock options could impact employee morale or retention.

Future Outlook

The future outlook depends on the successful completion and integration of the merger with Concentra Biosciences.

Industry Context

Mergers and acquisitions are common in the biotechnology industry, often driven by the desire to consolidate resources, technologies, and pipelines.

Stakeholder Impact

• Shareholders may be impacted by the merger and its potential effects on the company's value.
• Employees may be affected by potential changes in roles or responsibilities following the merger.

Key Dates

Keywords

stock options, merger, Allakos Inc., director, Form 4, beneficial ownership, Concentra Biosciences, Concentra Merger Sub III, cancellation